# Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®

> **NCT00731081** · — · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 8 (actual)

## Conditions studied

- Pompe Disease (Late-Onset)
- Glycogen Storage Disease Type II (GSD II)
- Glycogenesis 2 Acid Maltase Deficiency

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00731081
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731081, "Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00731081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*